|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.77 BRL | +5.20% |
|
+5.36% | +5.78% |
| 02/07 | Amgen Wins Preliminary Injunction to Block Colorado From Imposing Price Cap on Arthritis Drug | MT |
| 02/07 | Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial | DJ |
| Market Cap | 20TCr 1,04300Cr 18TCr 16TCr 15TCr 29TCr 19,22400Cr 29TCr 1,94700Cr 76TCr 9,44100Cr 76TCr 74TCr 32,57900Cr | P/E 2026 * |
24.4x | P/E 2027 * | 22.5x |
|---|---|---|---|---|---|
| Enterprise Value | 24TCr 1,25900Cr 21TCr 20TCr 18TCr 35TCr 23,19400Cr 35TCr 2,35000Cr 91TCr 11,39100Cr 91TCr 89TCr 39,30800Cr | EV / Sales 2026 * |
6.45x | EV / Sales 2027 * | 6.15x |
| Free-Float |
99.78% | Yield 2026 * |
2.7% | Yield 2027 * | 2.85% |
Last Transcript: Amgen Inc.
| 1 day | +5.20% | ||
| 1 week | +5.36% | ||
| Current month | +5.20% | ||
| 1 month | +14.10% | ||
| 3 months | +11.08% | ||
| 6 months | +12.77% | ||
| Current year | +5.78% |
| 1 week | 65.66 |  | 69.77 |
| 1 month | 62.29 | | 69.77 |
| Current year | 48.4 | | 78.13 |
| 1 year | 48.4 | | 78.13 |
| 3 years | 38 | | 78.13 |
| 5 years | 37.52 | | 78.13 |
| 10 years | 15.78 | | 78.13 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 01/05/2012 |
| Director of Finance/CFO | 62 | 13/05/2010 | |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 01/01/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 01/01/2013 |
Tyler Jacks
BRD | Director/Board Member | 65 | 01/01/2012 |
Robert Eckert
BRD | Director/Board Member | 71 | 01/01/2012 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.20% | +5.36% | - | - | 20TCr | |
| +1.86% | +0.48% | +55.50% | +163.08% | 1,08200Cr | |
| +3.57% | +3.29% | +68.60% | +61.03% | 63TCr | |
| +3.99% | +3.05% | +37.93% | +93.37% | 46TCr | |
| +3.86% | +1.85% | +31.30% | +24.86% | 34TCr | |
| -0.56% | +2.80% | +39.13% | +28.20% | 30TCr | |
| -0.08% | +1.52% | +29.96% | +42.13% | 29TCr | |
| -1.54% | +3.56% | -25.96% | -40.53% | 23TCr | |
| +4.21% | +2.65% | +17.47% | +71.11% | 16TCr | |
| +1.84% | +0.12% | -4.18% | -33.64% | 14TCr | |
| Average | +2.24% | +4.17% | +27.75% | +45.51% | 40.4TCr | |
| Weighted average by Cap. | +2.31% | +5.28% | +40.86% | +78.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.78TCr 20TCr 3.3TCr 3.03TCr 2.83TCr 5.36TCr 3,59500Cr 5.44TCr 36TCr 14TCr 1,76500Cr 14TCr 14TCr 6,09200Cr | 3.87TCr 20TCr 3.39TCr 3.11TCr 2.9TCr 5.5TCr 3,68600Cr 5.58TCr 37TCr 15TCr 1,81000Cr 15TCr 14TCr 6,24600Cr |
| Net income | 823.15Cr 4.25TCr 719.91Cr 660.73Cr 616.79Cr 1.17TCr 78TCr 1.19TCr 7.94TCr 3.09TCr 38TCr 3.09TCr 3.02TCr 1,32800Cr | 886.48Cr 4.58TCr 775.3Cr 711.57Cr 664.24Cr 1.26TCr 84TCr 1.28TCr 8.55TCr 3.32TCr 41TCr 3.33TCr 3.26TCr 1,43000Cr |
| Net Debt | 4.17TCr 22TCr 3.65TCr 3.35TCr 3.12TCr 5.92TCr 3,97000Cr 6.01TCr 40TCr 16TCr 1,95000Cr 16TCr 15TCr 6,72900Cr | 3.61TCr 19TCr 3.15TCr 2.89TCr 2.7TCr 5.12TCr 3,43300Cr 5.2TCr 35TCr 14TCr 1,68600Cr 14TCr 13TCr 5,81700Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | R$69.10 | +4.19% | 1,015 |
| 29/26/29 | R$66.32 | +0.15% | 1,728 |
| 26/26/26 | R$66.22 | +0.53% | 522 |
| 25/26/25 | R$65.87 | +0.81% | 1,531 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
- AMGN34 Stock
Select your edition
All financial news and data tailored to specific country editions
